Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)
Vir Biotechnology recorded quarterly Non-Current Deffered Revenue of $9.4 million in Q3 2025, up 518.15% quarter-over-quarter from $1.5 million in Q1 2024.
Vir Biotechnology's Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $9.4 million for Q3 2025.
- In Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $9.4 million; the TTM figure through Sep 2025 stood at $9.4 million (changed N/A YoY), while the FY2023 annual figure was $1.5 million, down 97.13% from the prior year.
- Non-Current Deffered Revenue came in at $9.4 million for Q3 2025 at Vir Biotechnology, up from $1.5 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $55.5 million in Q2 2021 to a low of $1.5 million in Q4 2023.
- A 5-year average of $25.5 million and a median of $7.6 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue soared 1354.68% in 2021 and sank 97.13% in 2023, its largest moves.
- Vir Biotechnology's Non-Current Deffered Revenue stood at $3.8 million in 2021, then surged by 1294.68% to $53.2 million in 2022, then tumbled by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then surged by 518.15% to $9.4 million in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $9.4 million, $1.5 million, and $1.5 million for Q3 2025, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.43 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 53.21 Mn |
| Jun 30, 2023 | 53.21 Mn |
| Mar 31, 2023 | 53.21 Mn |
| Dec 31, 2022 | 53.21 Mn |
| Sep 30, 2022 | 54.65 Mn |
| Jun 30, 2022 | 4.42 Mn |
| Mar 31, 2022 | 5.87 Mn |
| Dec 31, 2021 | 3.82 Mn |
| Sep 30, 2021 | 3.82 Mn |
| Jun 30, 2021 | 55.50 Mn |
| Mar 31, 2021 | 3.82 Mn |
| Dec 31, 2020 | 3.82 Mn |
| Sep 30, 2020 | 3.82 Mn |
| Jun 30, 2020 | 3.82 Mn |
| Mar 31, 2020 | 6.56 Mn |
| Dec 31, 2019 | 12.67 Mn |
| Sep 30, 2019 | 8.41 Mn |
| Dec 31, 2018 | 6.56 Mn |